

Journalbeiträge

1. Becker F, Junker K, Parr M, Hartmann A, Füssel S, Toma M, Grobholz R, Pflugmann T, Wullich B, Strauss A, Behnes CL, Otto W, Stöckle M, Jung V (2013) Collecting duct carcinomas represent a unique tumor entity based on genetic alterations. PLOS ONE, 8(10): e78137.
2. Behnes CL, Bedke J, Schneider S, Küffer S, Strauss A, Bremmer F, Ströbel P, Radzun HJ (2013) Myoglobin expression in renal cell carcinoma is regulated by hypoxia. EXP MOL PATHOL, 95(3): 307-12.
3. Behnes CL, Schlegel C, Shoukier M, Magiera I, Henschke F, Schwarz A, Bremmer F, Loertzer H (2013) Hereditary papillary renal cell carcinoma primarily diagnosed in a cervical lymph node: a case report of a 30-year-old woman with multiple metastases. BMC UROL, 13: 3.
4. Bolenz C, Auer M, Ströbel P, Heinzlbecker J, Schubert C, Trojan L (2013) The lymphatic system in clinically localized urothelial carcinoma of the bladder: morphologic characteristics and predictive value. UROL ONCOL-SEMIN ORI, 31(8): 1606-14.
5. Buchner A, May M, Burger M, Bolenz C, Herrmann E, Fritsche HM, Ellinger J, Höfner T, Nuhn P, Gratzke C, Brookman-May S, Melchior S, Peter J, Moritz R, Tilki D, Gilfrich C, Roigas J, Zacharias M, Hohenfellner M, Haferkamp A, Trojan L, Wieland WF, Müller SC, Stief CG, Bastian PJ (2013) Prediction of outcome in patients with urothelial carcinoma of the bladder following radical cystectomy using artificial neural networks. EJSO-EUR J SURG ONC, 39(4): 372-9.
6. Hasibeder A, Venkataramani V, Thelen P, Radzun HJ, Schweyer S (2013) Phytoestrogens regulate the proliferation and expression of stem cell factors in cell lines of malignant testicular germ cell tumors. INT J ONCOL, 43(5): 1385-94.
7. Heidenreich A, Scholz HJ, Rogenhofer S, Arsov C, Retz M, Müller SC, Albers P, Gschwend J, Wirth M, Steiner U, Miller K, Heinrich E, Trojan L, Volkmer B, Honecker F, Bokemeyer C, Keck B, Otremba B, Ecstein-Fraisse E, Pfister D (2013) Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. EUR UROL, 63(6): 977-82.
8. Heinzlbecker J, Katzmarzik M, Weiss C, Trojan L, Haecker A (2013) During twenty years of Cisplatin-based therapy the face of nonseminomatous testicular germ cell tumors is still changing: an evaluation of presentation, management, predictive factors and survival. Int Braz J Urol, 39(1): 10-21.
9. Heinzlbecker J, Kempf KM, Kurz K, Steidler A, Weiss C, Jackson DG, Bolenz C, Haecker A, Trojan L (2013) Lymph vessel density in seminomatous testicular cancer assessed with the specific lymphatic endothelium cell markers D2-40 and LYVE-1: correlation with pathologic parameters and clinical outcome. UROL ONCOL-SEMIN ORI, 31(7): 1386-94.
10. Loertzer H, Schneider P (2013) [Stress incontinence in elderly women]. UROLOGE, 52(6): 813-20.
11. Loertzer H, Strauß A, Ringert RH, Schneider P (2013) Laser-supported partial laparoscopic nephrectomy for renal cell carcinoma without ischaemia time. BMC UROL, 13: 31.
12. Lumma PP, Schneider P, Strauss A, Plothe KD, Thelen P, Ringert RH, Loertzer H (2013) Impact of ureteral stenting prior to ureterorenoscopy on stone-free rates and complications. WORLD J UROL, 31(4): 855-9.
13. May M, Bastian PJ, Brookman-May S, Fritsche HM, Tilki D, Otto W, Bolenz C, Gilfrich C, Trojan L, Herrmann E, Moritz R, Tiemann A, Müller SC, Ellinger J, Buchner A, Stief CG, Wieland WF, Höfner T, Hohenfellner M, Haferkamp A, Roigas J, Zacharias M, Nuhn P, Burger M (2013) Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a. UROL ONCOL-SEMIN ORI, 31(7): 1141-7.
14. Thelen P, Heinrich E, Bremmer F, Trojan L, Strauss A (2013) Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation. PROSTATE, 73(15): 1699-709.
15. Thelen P, Krahn L, Bremmer F, Strauss A, Brehm R, Loertzer H (2013) Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma. INT J MOL MED, 31(2): 339-46.
16. Witt D, Burfeind P, von Hardenberg S, Opitz L, Salinas-Riester G, Bremmer F, Schweyer S, Thelen P, Neesen J, Kaulfuss S (2013) Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2. CARCINOGENESIS, 34(5): 1115-24.

Medizinische Dissertationen

1. Kessel FJ, Dr. med. (2013) Behandlungserfolg, Lebensqualität und Zufriedenheit von Patienten nach Implantationen eines künstlichen Schließmuskels zur Harninkontinenztherapie. Dissertation Universität Göttingen.
2. Schulz A, Dr. med. (2013) Molekularpathologie seltener Sarkomentitäten des Urogenitaltraktes. Dissertation Universität Göttingen.